Correction: Molecular profiling of cetuximab and bevacizumab treatment of colorectal tumours reveals perturbations in metabolic and hypoxic response pathways.

Present: Due to an error during manuscript preparation, loading control (GAPDH) was omitted from Figure 5.

Figure 5

Validation of anti-tumour effects of cetuximab and bevacizumab mediated through altered cellular metabolism

Proteins were extracted from tumour xenografts for each treatment cohort (independent from the tumour xenograft lysates performed for proteomic profiling), obtained from pooled tumour xenograft samples from the validation experimental group (n=3). Immunoblotting analysis of the expression of ATP5B, SDC2, GPD2, ARF4 in both LIM1215 and HT-29 tumour xenograft lysates was performed (n=3; pooled for each treatment cohort, independent biological replicates performed for each antibody). Loading control (GAPDH; rabbit anti-GAPDH (Cell Signaling Technology; 1:1000)).

Corrected: Correct Figure 5 is provided below. Authors sincerely apologize for this oversight.

Original article: Oncotarget. 2015; 6(35): 38166-80. doi: 10.18632/oncotarget.6241.